TEGOSCIENCE INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18,210 KRW | -3.45% |
|
+3.47% | +24.22% |
| 2023 | TegoScience Inc.(KOSDAQ:A191420) dropped from S&P Global BMI Index | CI |
| 2023 | TegoScience Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| Sales 2022 | 7.68B 5.56M | Sales 2023 | 7.77B 5.63M | Capitalization | 117B 84.98M |
|---|---|---|---|---|---|
| Net income 2022 | 265M 192K | Net income 2023 | -2.32B -1.68M | EV / Sales 2022 | 9.97 x |
| Net cash position 2022 | 21.16B 15.32M | Net cash position 2023 | 19.37B 14.02M | EV / Sales 2023 | 12.6 x |
| P/E ratio 2022 |
370
x | P/E ratio 2023 |
-50.5
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 56.75% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.45% | ||
| 1 week | +3.47% | ||
| Current month | -15.50% | ||
| 1 month | -15.50% | ||
| 3 months | +34.89% | ||
| 6 months | +25.59% | ||
| Current year | +24.22% |
1 week
18 110.00
19 850.00
1 month
17 250.0026 100.00
Current year
10 710.0026 100.00
1 year
7 430.0026 100.00
3 years
7 430.0031 300.00
5 years
7 430.0037 200.00
10 years
7 430.0073 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sae-Wha Jeon
FOU | Founder | 58 | 01-03-19 |
| 61 | - | ||
Han-Kyu Jang
BRD | Director/Board Member | 51 | 01-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sae-Wha Jeon
FOU | Founder | 58 | 01-03-19 |
Jae-Wook Jeon
FOU | Founder | 61 | 01-03-19 |
Han-Kyu Jang
BRD | Director/Board Member | 51 | 01-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 18,210 | -3.45% | 12,904 |
| 24-05-30 | 18,860 | +0.48% | 8,187 |
| 24-05-29 | 18,770 | -3.40% | 30,199 |
| 24-05-28 | 19,430 | +1.62% | 34,663 |
| 24-05-27 | 19,120 | +4.77% | 50,347 |
End-of-day quote Korea S.E., May 30, 2024
More quotes
Tego Science,Inc. is a Korea-based company mainly engaged in the research and development, manufacture and distribution of wound-healing skin cell therapy products. The Companyâs products mainly consist of cell therapy products, and laboratory cultured skin models.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +24.22% | 110M | |
| -2.29% | 89.38B | |
| -3.95% | 37.92B | |
| -13.07% | 32.04B | |
| +63.05% | 26.03B | |
| -22.14% | 14.14B | |
| -7.96% | 12.88B | |
| -9.33% | 11.77B | |
| -46.33% | 10.85B | |
| +5.77% | 8.92B |
- Stock Market
- Equities
- A191420 Stock
